News | Cath Lab | June 14, 2019

Using IVUS Guided Stent Implantation to Reduce Contrast in Patients With Chronic Kidney Disease

SCAI research compares innovative treatment approach to traditionally used angiography-guidance

Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).

June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting stent (DES) implantation on patients with chronic kidney disease (CKD). Results showed that CKD patients treated with IVUS-guided DES implantation had better outcomes compared to those who received the traditional angiography guidance DES implantation at 12 months. The prespecific subgroup analysis of the prospective, multicenter, randomized ULTIMATE Trial was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions in May.

Chronic kidney disease is a growing worldwide health issue affecting one in 10 individuals, according to the National Kidney Foundation. Patients with CKD are more than 30 percent likely to have cardiovascular disease which is the leading cause of death, according to the National Institutes of Health (NIH). While several randomized trials and observational studies have established the clinical benefits of IVUS-guided DES implantations for patients with complex lesions, the treatment option remains controversial for patients with CKD due to longer procedural time and perceived potential risks of acute renal failure and atheroembolism.

“The present study, which was a prespecified subgroup analysis of the ULTIMATE trial, was designed to explore the impacts of IVUS-guided second-generation DES implantations on patients with CKD.” said Junjie Zhang, M.D., Ph.D., Nanjing First Hospital, Nanjing Medical University, China. “The results from our study show that compared to angiography guidance procedures, IVUS-guided DES implantation is a new and effective treatment approach. This procedure has the potential to significantly decrease target vessel failure in CKD patients and, ultimately, improve their quality of life.

The study assessed 1,443 patients of whom 723 underwent IVUS-guided DES implantations and 720 underwent angiography-guided DES implantations from August 2014 to May 2017. The inclusion criteria were patients who had silent ischemia, stable or unstable angina, or myocardial infarctions from the onset of chest pain to admission, as well as de novo coronary lesions that were eligible for DES implantation. The trial was conducted in eight hospitals throughout China and was approved at each participating center. CKD was present in 349 (24.2 percent) patients. CKD patients were older and more frequently presented with a history of stroke, hypertension, symptomatic heart failure (HF), and lower left ventricular ejection fraction (LVEF).

At 12 months, the target vessel failure (TVF) in the CKD group was 7.2 percent, significantly higher than 3.2 percent in the non-CKD group, which was mainly driven by increased risk of cardiac death in CKD patients, compared to non-CKD patients (2.9 vs. 0.5 percent). Moreover, there were 25 TVFs in CKD patients, with seven TVFs (3.9 percent) in the IVUS group and 18 TVFs (10.7 percent) in the angiography group. The reduced risk of TVF in the IVUS group for CKD patients was mainly driven by the lower risk of Target Vessel MI (TVMI) (0.6 vs. 3.6 percent) and Target Vessel Revascularization (TVR) (1.1 vs. 4.7 percent).

To further assess long-term efficacy of IVUS-guided DES implantation as a treatment option, the authors of this study call for a broader randomized trial.

Watch a VIDEO interview with Zhang on this trial from TCT 2018.

For more information:

Link to all the SCAI 2019 lake-breaking trials.

Related Content

Canon Medical Launches Alphenix Encore Plus Program
News | Angiography | October 09, 2019
In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-date with the most...
The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Mentice and Siemens Healthineers Integrate VIST Virtual Patient With Artis Icono Angiography System
Technology | Angiography | June 24, 2019
Siemens Healthineers and Mentice AB announced the collaboration to fully integrate Mentice’s VIST Virtual Patient into...
Medis QAngio XA 3D Receives FDA 510k Clearance
Technology | Angiography | June 04, 2019
Medis Medical Imaging Systems B.V. has received clearance from the U.S. Food and Drug Administration for its QAangio XA...
iSchemaView Launches RAPID Angio
Technology | Angiography | March 01, 2019
iSchemaView announced the release of RAPID Angio, a complete neuroimaging solution for the angiography suite that...
Videos | Angiography | February 08, 2019
This is an example of an arterial venous malformation (AVM) in the brain imaged on a ...
Canon Medical Debuts Alphenix 4-D CT at RSNA 2018
Technology | Angiography | February 06, 2019
Canon Medical Systems USA Inc. recently introduced a new angiography configuration featuring its Alphenix Sky + C-arm...
Canon Medical Systems Launches Alphenix Interventional Imaging Line
Technology | Angiography | February 04, 2019
Canon Medical Systems USA recently introduced its next generation of interventional systems – the Alphenix platform....
An example of multimodality image fusion with live angiography to enhance soft-tissue visualization during complex procedures. This example is from Siemen's new TrueFusion software released in 2018. Advances in angiography imaging.

An example of multimodality image fusion with live angiography to enhance soft-tissue visualization during complex procedures. This example is from Siemen's new TrueFusion software released in 2018. 

Feature | Angiography | January 28, 2019 | Dave Fornell, Editor
There are a few recent trends in X-ray...
Overlay Init